Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26545438 | 0.93 | EGLN2 (0.34) | EGLN2TSHRRIPK1 | |
| SCHEMBL26200118 | 0.86 | EGFR (0.41) | EGLN2TSHR | |
| SCHEMBL26545444 | 0.83 | TSHR (0.44) | TSHR | |
| SCHEMBL26209285 | 0.83 | EGLN2 (0.34) | EGLN2TSHR | |
| SCHEMBL26545442 | 0.80 | HTT (0.42) | TSHR | |
| SCHEMBL26545440 | 0.79 | DEGS1 (0.42) | — | |
| SCHEMBL26206054 | 0.78 | EGFR (0.41) | EGLN2TSHR | |
| SCHEMBL26229442 | 0.76 | PKM (0.36) | EGLN2TSHRGRM5 | |
| SCHEMBL26229443 | 0.75 | TSHR (0.44) | TSHRGRM5 | |
| SCHEMBL26229441 | 0.74 | MEN1 (0.38) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322813-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322813-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | EGLN2 771/4885TSHR 4522/4885P2RY1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.